SEC Form 4 · accession 0001628280-26-053755
Arcutis Biotherapeutics, Inc. · ARQT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick Burnett
Officer — See Remarks
Period of report
Aug 3, 2026
Accepted (ET)
Aug 5, 2026 · 9:42 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001787306
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 3, 2026 | S | 955 | $26.1168 | D | 119,289 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
- F2The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.72 to $26.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Remarks
Reporting Person's title: EVP, Chief Medical Officer